PubMatic and DIGITS Agency Bring Advanced AdTech to Local Grocery and Convenience Stores Strategic Partnership to Launch with Fareway Stores and Vroom Delivery, Offering Precise Digital Advertising, Measurement and Performance at the Local Level NO-HEADQUARTERS/REDWOOD CITY, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- DIGITS, a leading independent retail media agency, and PubMatic (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, announce their strategic partnership to leverage PubMatic’s , a scalable full-funnel commerce media ...
Xumo and PubMatic Partner to Expand Programmatic Advertising Integration Unlocks Reach and Targeting for Advertisers Across Xumo’s Premium Content PHILADELPHIA and REDWOOD CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Xumo, a streaming platform joint venture between Comcast and Charter, and PubMatic (Nasdaq: PUBM) an independent technology company delivering digital advertising’s supply chain of the future, announced a partnership today to make Xumo’s premium inventory programmatically available to advertisers via PubMatic. As the digital advertising ecosystem becomes more crowded an...
PubMatic to Participate at Upcoming Financial Conferences NO-HEADQUARTERS/REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that members of its management team are scheduled to participate at the following upcoming financial conferences. Details for the events are as follows: Wolfe Research Small and Mid-Cap Conference in New York on Wednesday, December 4, 2024Raymond James TMT and Consumer Conference in New York on Wednesday December 11, 20...
PubMatic Announces Third Quarter 2024 Financial Results Delivered Q3 results ahead of guidanceDelivered revenue of $71.8 million, up 13% over Q3 2023; Revenue from omnichannel video up 25%; Gross profit was $46.3 million, up 23% over Q3 2023Net loss of $(0.9) million or (1)% margin; Adjusted EBITDA of $18.5 million or 26% margin; Repurchased 3.6 million shares year to date, representing 6.5% of fully diluted shares as of September 30, 2024 NO-HEADQUARTERS/REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering di...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2024. “We were thrilled to announce positive and statistically significant topline data from the pivotal Phase 3 SAPPHIRE trial, a major achievement that underscores apitegromab’s potential to redefine the stand...
SoundCloud Selects PubMatic to Enhance Access to Programmatic Advertising on a Global Scale The international partnership will enable programmatic inventory on the artist-first platform, which has 175 million monthly listeners NO-HEADQUARTERS/REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SoundCloud, the artist-first platform that empowers artists and fans to connect and share through music, and PubMatic, an independent technology company delivering digital advertising’s supply chain of the future, announce a new strategic partnership offering SoundCloud’s premium advertising i...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced new preclinical data that support the potential of SRK-439, a highly selective investigational antimyostatin antibody, to increase lean mass and lower fat mass gain when taken with metformin. These data will be presented by Melissa Fulham, Ph.D., of Scholar Rock, at the ObesityWeek conference ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. To access the live conference call, participants may register . The live audio webcast of the call will be available under...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.